STAT3 and breast carcinoma: Notably, we presented evidence for the first time that activated forms of HER2 and HER3 receptor proteins as well as cytoplasmic STAT3 phospho-PTMs forms in breast cancer cells can be directly targeted using our approach, which was referred to as the “TRIM-ing” process (Figure 3).